NanoVibronix, Inc.

Equities

NAOV

US63008J6038

Medical Equipment, Supplies & Distribution

Market Closed - Nasdaq Other stock markets 02:00:01 05/06/2024 am IST			5-day change	1st Jan Change
0.79 ^USD	-2.82%		+1.78%	-31.30%

22/05	NanoVibronix, Inc. Announces Commencement of UroShield Clinical Study at the University of Michigan	CI
15/05	NanoVibronix, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

Nanovibronix, Inc. Announces Resignation of William Stern as Director

October 17, 2017 at 02:31 am IST

NanoVibronix, Inc. announced that on October 11, 2017, William Stern Ph.D, President and member of the board of directors of the company, submitted his resignation as a member of the board of directors which resignation became effective immediately. He will continue to serve in his role as President of the company.

Latest news about NanoVibronix, Inc.

NanoVibronix, Inc. Announces Commencement of UroShield Clinical Study at the University of Michigan	22/05	CI
NanoVibronix, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	15/05	CI
NanoVibronix Signs Multiyear Distribution Deal With CB Medical for UroShield	14/05	MT
NanoVibronix, Inc. Announces Distribution Agreement with Cb Medical, Llc for the Distribution of Uroshield	14/05	CI
NanoVibronix Announces PainShield Will Be Included in Department of Veteran Affairs? FSS Contract Award	01/05	CI
NanoVibronix, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	09/04	CI
NanoVibronix, Inc. Enters into Letter of Intent with APOGEPHA Arzneimittel GmbH to Explore European Distribution Opportunity	04/12	CI
NanoVibronix, Inc. Signs Research Agreement for Clinical Study of UroShield with University of Michigan	28/11	CI
NanoVibronix, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	14/11	CI
Investors Eye Fed Moves as US Futures Trend Lower in Friday's Premarket	20/23/20	MT
NanoVibronix, Inc. Gains Approval for Inclusion of UroShield Products in NHS Prescription Services' Drug Tariff	27/23/27	CI
NanoVibronix Files Registration Statement on Behalf of Selling Shareholders	13/23/13	MT
NanoVibronix to Raise $5 Million Through Securities Placement	31/23/31	MT
Top Midday Gainers	30/23/30	MT
NanoVibronix, Inc. announced that it expects to receive $5 million in funding	30/23/30	CI
NanoVibronix Says It's Working to Understand Implications of CMS Decision Related to PainShield Device	30/23/30	MT
NanoVibronix, Inc. Applies for Inclusion of Uroshield Products in Nhs Prescription Services' Drug Tariff	28/23/28	CI
NanoVibronix Extends Distribution Agreement With Ultra Pain Products for Ultrasound Therapy Devices; Shares Rise	23/23/23	MT
NanoVibronix Extends Distribution Agreement with Its Largest Distributor for PainShield and PainShield Plus	23/23/23	CI
NanoVibronix, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	12/23/12	CI
NanoVibronix Announces Distribution Agreement with Mio-Guard	14/23/14	CI
NanoVibronix, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	16/23/16	CI
NanoVibronix, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	18/23/18	CI
NanoVibronix, Inc. Receives Positive Final Results of Independent Lifecycle Testing of PainShield Prompted by Centers for Medicare and Medicaid Services	28/23/28	CI
NanoVibronix Files Provisional Patent Application in US for UroShield Ultra; Shares Jump	21/23/21	MT

Chart NanoVibronix, Inc.

Duration

Period

More charts

Company Profile

NanoVibronix, Inc. is a medical device company. The Company develops medical devices utilizing its patented low intensity surface acoustic wave technology. Its products include UroShield and PainShield. UroShield is an ultrasound-based product that is designed to prevent bacterial colonization and biofilm in urinary catheters, increase antibiotic efficacy and decrease pain and discomfort associated with urinary catheter use. UroShield Ultra is similar to UroShield, but is designed to prevent bacterial colonization and biofilm formation in urinary catheters. PainShield is a patch-based therapeutic ultrasound technology to treat pain, muscle spasm and joint contractures by delivering a localized ultrasound effect to treat pain and induce soft tissue healing in a targeted area. Its PainShield family of products includes PainShield MD, PainShield Plus and WoundShield. WoundShield is a patch-based therapeutic ultrasound device intended to facilitate tissue regeneration and wound healing.

Sector

Medical Equipment, Supplies & Distribution

More about the company

Income Statement Evolution

More financial data

Sector Other Medical Equipment, Supplies & Distribution

	1st Jan change	Capi.
NANOVIBRONIX, INC.	-31.30%	22L
ABBOTT LABORATORIES	-6.03%	18TCr
MEDTRONIC PLC	+1.08%	11TCr
BECTON, DICKINSON AND COMPANY	-2.19%	6.89TCr
DEXCOM, INC.	-5.98%	4.64TCr
CENCORA, INC.	+12.31%	4.54TCr
HOYA CORPORATION	+7.38%	4.33TCr
METTLER-TOLEDO INTERNATIONAL, INC.	+15.98%	3TCr
TERUMO CORPORATION	+16.10%	2.52TCr
WEST PHARMACEUTICAL SERVICES, INC.	-9.57%	2.32TCr

Other Medical Equipment, Supplies & Distribution